EHA 2026 | Genomic profiling is redefining risk stratification in acute lymphoblastic leukemia
Anthony Moorman, PhD, Newcastle University, Newcastle, UK, discusses how advances in genomic and cytogenetic profiling are reshaping risk stratification in acute lymphoblastic leukemia (ALL). Prof. Moorman explains how the identification of numerous new ALL subtypes is enabling increasingly personalized treatment approaches, while also highlighting the challenge of integrating genomic data with established clinical risk factors such as age, white cell count, immunophenotype, and treatment response. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
